ORKA

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2003, for Nuvelo, Inc. (formerly Hyseq, Inc.). The company is a biopharmaceutical firm focused on the discovery and development of novel protein-based products. A material event during this period was the completion of a merger with Variagenics, Inc. on January 31, 2003, which significantly altered the company's asset base and cash position. The financial results for the three and six months ended June 30, 2003, include the operations of Variagenics commencing from February 1, 2003.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Contract revenues dropped significantly to $0.4 million for the quarter (from $6.7 million in Q2 2002) and $1.7 million for the six months (from $11.9 million in the prior year). This decrease is primarily attributed to the completion of the agricultural gene discovery collaboration with BASF Plant Science LLC in January 2003 and the conclusion of collaborations with Chiron and Agilent in 2002.
• Increased Net Loss: The net loss for the quarter increased to $16.3 million from $8.1 million in the prior year. The six-month loss rose to $29.9 million from $27.0 million. The increase is driven by lower revenues and one-time costs, including $3.5 million in lease transaction costs related to the decision not to exercise a facility purchase option and costs associated with the Variagenics merger.
• Liquidity Improvement: Cash and cash equivalents increased from $2.2 million at December 31, 2002, to $20.5 million at June 30, 2003. This improvement was largely due to the cash infusion from the Variagenics merger, which provided approximately $50.8 million in total assets (cash, equivalents, and short-term investments).
• Operating Expenses: Research and development expenses decreased due to cost savings from the BASF collaboration completion and facility lease terminations. However, General and Administrative expenses increased due to merger-related costs and lease termination fees.

Guidance, Outlook, and Risks

• Strategic Focus: Management is prioritizing the development of alfimeprase, a novel thrombolytic agent currently in Phase II trials for peripheral arterial occlusion and catheter occlusion. The company intends to monetize non-core assets, including its microarray business and pharmacogenomic technology, to fund biopharmaceutical programs.
• Liquidity Outlook: Management expects current cash balances, anticipated business development inflows, and the line of credit to fund operations through 2004. A Form S-3 registration statement was filed on July 8, 2003, allowing for the sale of up to $50 million in securities.
• Cost Control: The company has implemented a partial hiring freeze, a freeze on capital expenditures, and a delay in facility expansion plans to conserve cash.
• Risks:
  • Delisting Risk: The company faces potential delisting from the Nasdaq National Market if the stock price falls below $1.00 or if shareholders' equity drops below $10 million.
  • Financing Needs: Continued profitability is not expected in the foreseeable future. The company may need to raise additional capital, which could result in significant dilution.
  • Regulatory Uncertainty: Success depends on FDA approval for product candidates, which is uncertain and costly.
  • Legal Proceedings: The company is defending a securities class action lawsuit inherited from Variagenics regarding its 2000 IPO; a settlement is being negotiated.

Investor Verification Checklist

• Cash Runway: Verify if the projected funding through 2004 remains accurate given the high burn rate ($24.4 million used in operations in the first half of 2003).
• Alfimeprase Progress: Monitor the results of the Phase II "proof-of-concept" studies for alfimeprase, expected to complete by the end of 2003.
• Stock Price Volatility: Assess the risk of Nasdaq delisting given the stock price range of $0.71 to $2.60 in the first half of 2003.
• Merger Integration Costs: Track the finalization of severance payments and facility lease termination costs associated with the Variagenics merger and the Callida restructuring.
• Debt Covenants: Review the terms of the line of credit with Chairman Dr. George B. Rathmann and the note held by Affymetrix, specifically regarding prepayment triggers based on market capitalization.